MA38571A1 - Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique - Google Patents
Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostiqueInfo
- Publication number
- MA38571A1 MA38571A1 MA38571A MA38571A MA38571A1 MA 38571 A1 MA38571 A1 MA 38571A1 MA 38571 A MA38571 A MA 38571A MA 38571 A MA38571 A MA 38571A MA 38571 A1 MA38571 A1 MA 38571A1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- hemoglobin
- treatment
- therapeutic agent
- therapeutic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 102000001554 Hemoglobins Human genes 0.000 title abstract 5
- 108010054147 Hemoglobins Proteins 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 238000002059 diagnostic imaging Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 239000000975 dye Substances 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000015634 Rectal Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000010859 live-cell imaging Methods 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 206010038038 rectal cancer Diseases 0.000 abstract 1
- 201000001275 rectum cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
Abstract
L'invention concerne une composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine pour le traitement du cancer. La fraction hémoglobine peut cibler les cellules cancéreuses, et la fraction thérapeutique (c'est-à-dire l'agent actif/le médicament thérapeutique) peut les détruire efficacement. L'agent thérapeutique à base d'hémoglobine de la présente invention peut être utilisé pour le traitement de différents cancers, notamment le cancer du pancréas, la leucémie, le cancer de la tête et du cou, le cancer du côlon et du rectum, le cancer du poumon, le cancer du sein, le cancer du foie, le cancer du rhinopharynx, le cancer de l'œsophage, le cancer de la prostate, le cancer de l'estomac et le cancer du cerveau. La composition peut être utilisée seule ou en association avec un ou plusieurs autres agents thérapeutiques, par exemple un agent chimiothérapeutique pour obtenir un effet synergique sur le traitement du cancer, en inhibant les métastases et/ou en réduisant la récidive du cancer. Le conjugué à base d'hémoglobine et de 5fu contenant deux colorants et/ou le conjugué à base d'hémoglobine et de 5fu contenant un colorant selon l'invention peuvent également être utilisés en imagerie des cellules vivantes et en imagerie diagnostique.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822463P | 2013-05-13 | 2013-05-13 | |
| PCT/US2014/037749 WO2014186301A1 (fr) | 2013-05-13 | 2014-05-13 | Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique |
| US14/275,885 US9636404B2 (en) | 2013-05-13 | 2014-05-13 | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38571A1 true MA38571A1 (fr) | 2017-10-31 |
| MA38571B1 MA38571B1 (fr) | 2018-10-31 |
Family
ID=51864923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38571A MA38571B1 (fr) | 2013-05-13 | 2014-05-13 | Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9636404B2 (fr) |
| EP (1) | EP3001813B1 (fr) |
| JP (1) | JP6392855B2 (fr) |
| KR (1) | KR102013015B1 (fr) |
| CN (1) | CN105407911B (fr) |
| AU (1) | AU2014265659B2 (fr) |
| BR (1) | BR112015028340A2 (fr) |
| CA (1) | CA2911414C (fr) |
| CL (1) | CL2015003343A1 (fr) |
| EA (1) | EA032164B1 (fr) |
| HK (2) | HK1222574A1 (fr) |
| IL (1) | IL242422B (fr) |
| MA (1) | MA38571B1 (fr) |
| MX (1) | MX362001B (fr) |
| MY (1) | MY176175A (fr) |
| PH (1) | PH12015502536A1 (fr) |
| SA (1) | SA515370134B1 (fr) |
| SG (1) | SG11201509042YA (fr) |
| TW (1) | TWI610685B (fr) |
| WO (1) | WO2014186301A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014265659B2 (en) * | 2013-05-13 | 2017-03-30 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
| US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| MA40415A (fr) | 2014-09-03 | 2016-03-10 | Immunogen Inc | Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques |
| TR201606102A2 (tr) * | 2016-05-10 | 2016-10-21 | Tolgay Tuyan Ilhan | Karin i̇çi̇ uygulanan kanser tedavi̇leri̇nde oksi̇jen konsantrasyonu ölçümü yapabi̇len ve veri̇len oksi̇jen dozaji üzeri̇nde deği̇şi̇kli̇k yapmayi sağlayan ci̇haz |
| EP3471775A4 (fr) * | 2016-06-21 | 2020-02-19 | Therapure Biopharma Inc. | Administration de médicament ciblée sur l'hémoglobine pour le traitement du cancer |
| EP3555627B1 (fr) * | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Imagerie et thérapie ciblées par une protéine d'activation des fibroblastes (fap) |
| US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
| CN107153771B (zh) * | 2017-05-17 | 2020-06-30 | 许昌学院 | 一种药物分子的同步控制方法及其应用 |
| CA3070172A1 (fr) | 2017-07-18 | 2019-01-24 | VirTech Bio, Inc. | Substituts sanguins comprenant de l'hemoglobine et procedes de fabrication |
| CA3144719A1 (fr) * | 2019-07-19 | 2021-01-28 | Cheer Global Limited | Agents therapeutiques a base d'hemoglobine |
| CN114605338B (zh) * | 2022-05-11 | 2022-10-28 | 深圳厚存纳米药业有限公司 | 一种含尿嘧啶衍生物的纳米粒、核酸纳米复合物及其制备方法和用途 |
| CN116068189A (zh) * | 2023-04-07 | 2023-05-05 | 吉林重明生物科技有限公司 | 早期癌检测试剂及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5688488A (en) | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| MC2260A1 (fr) * | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
| ATE168014T1 (de) * | 1991-11-08 | 1998-07-15 | Somatogen Inc | Hämoglobine als arzneimittelabgabesystem |
| CA2188565A1 (fr) * | 1994-04-29 | 1995-11-09 | Meera Venkatesh | Composes thioether destines a la preparation d'agents chelateurs bifonctionnels pour des produits radiopharmaceutiques therapeutiques |
| US5998361A (en) * | 1996-10-18 | 1999-12-07 | University Of Maryland At Baltimore | Polymerized hemoglobin |
| US20050059576A1 (en) * | 1998-04-30 | 2005-03-17 | Adamson J. Gordon | Targeted delivery of antiviral compounds through hemoglobin bioconjugates |
| CA2236344A1 (fr) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Complexes hemoglobine-haptoglobine |
| DE60317303T2 (de) * | 2003-04-17 | 2008-06-19 | Ezio Panzeri | Hämoglobin-Konjugate |
| US7235639B2 (en) | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
| WO2010059315A1 (fr) * | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Lieurs de sérum-albumine humaine et conjugués de ceux-ci |
| US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US8084581B1 (en) * | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
| US20130052232A1 (en) * | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| US20140106004A1 (en) * | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| AU2014265659B2 (en) * | 2013-05-13 | 2017-03-30 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
-
2014
- 2014-05-13 AU AU2014265659A patent/AU2014265659B2/en active Active
- 2014-05-13 JP JP2016514013A patent/JP6392855B2/ja not_active Expired - Fee Related
- 2014-05-13 EP EP14798660.8A patent/EP3001813B1/fr active Active
- 2014-05-13 WO PCT/US2014/037749 patent/WO2014186301A1/fr active Application Filing
- 2014-05-13 MX MX2015015555A patent/MX362001B/es active IP Right Grant
- 2014-05-13 US US14/275,885 patent/US9636404B2/en active Active
- 2014-05-13 KR KR1020157032973A patent/KR102013015B1/ko active IP Right Grant
- 2014-05-13 EA EA201501065A patent/EA032164B1/ru not_active IP Right Cessation
- 2014-05-13 MY MYPI2015703946A patent/MY176175A/en unknown
- 2014-05-13 SG SG11201509042YA patent/SG11201509042YA/en unknown
- 2014-05-13 CN CN201480040021.4A patent/CN105407911B/zh active Active
- 2014-05-13 MA MA38571A patent/MA38571B1/fr unknown
- 2014-05-13 CA CA2911414A patent/CA2911414C/fr active Active
- 2014-05-13 BR BR112015028340A patent/BR112015028340A2/pt not_active Application Discontinuation
- 2014-05-13 TW TW103116929A patent/TWI610685B/zh not_active IP Right Cessation
-
2015
- 2015-11-03 IL IL242422A patent/IL242422B/en not_active IP Right Cessation
- 2015-11-05 PH PH12015502536A patent/PH12015502536A1/en unknown
- 2015-11-12 SA SA515370134A patent/SA515370134B1/ar unknown
- 2015-11-13 CL CL2015003343A patent/CL2015003343A1/es unknown
-
2016
- 2016-09-13 HK HK16110826.1A patent/HK1222574A1/zh unknown
- 2016-09-29 HK HK16111399.6A patent/HK1223037A1/zh unknown
-
2017
- 2017-03-27 US US15/469,978 patent/US10322180B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38571A1 (fr) | Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique | |
| JP2021059579A (ja) | 癌を処置するための医薬組合せ | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| Tozer et al. | Tumour vascular disrupting agents: combating treatment resistance | |
| US10105382B2 (en) | Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in ovarian cancer | |
| MA39907B1 (fr) | Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) | |
| EA201591932A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ | |
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
| Cheng et al. | Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death | |
| MA38376A1 (fr) | Composition pharmaceutique comprenant l'arginine déiminase de liaison à l'albumine pour le traitement ciblé du cancer | |
| Vargas et al. | Inhibition of HDAC increases the senescence induced by natural polyphenols in glioma cells | |
| WO2017210246A3 (fr) | Conjugués de pénicillamine et particules et formulations associées | |
| MA40791A (fr) | Ciblage lysosomal d'enzymes et utilisations associées | |
| MA56827B2 (fr) | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine | |
| WO2020146521A3 (fr) | Agents d'arni pour inhiber l'expression de hif-2 alpha (epas1), leurs compositions et méthodes d'utilisation | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| Sammons et al. | Copper suppression as cancer therapy: The rationale for copper chelating agents in BRAF V600 mutated melanoma | |
| WO2023141360A3 (fr) | Composés anti-b7-h3 et méthodes d'utilisation | |
| EA200801670A1 (ru) | Комбинированная противораковая терапия с перфузией изолированного органа | |
| Orsolic et al. | Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation | |
| EA202190748A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой | |
| Moskowitz | Relapsed and Refractory Hodgkin Lymphoma | |
| Spencer et al. | Depth of response and MRD with Daratumumab plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR |